Mark Molitch

List of Articles by Year in descending order

Source: //exaly.com/author-pdf/6459374/publications.pdf

Version: 2025-02-01

228 peer-reviewed articles	18,802 peer-reviewed citations	17149 63 peer-reviewed h-index	576762 3.66 score
287 documents	23208 doc citations	14512 71 h-index	35113 citing authors

#	Article	IF	Citations
1	Surveillance Imaging Strategies for Pituitary Adenomas: When, How Frequent, and When to Stop. Endocrine Practice, 2024, 30, 282-291.	2.0	9
2	Associations of Kidney Tubular Biomarkers With Incident Macroalbuminuria and Sustained Low eGFR in DCCT/EDIC. Diabetes Care, 2024, 47, 1539-1547.	5.6	14
3	Medical therapy of pituitary adenomas. , 2024, , 1-9.		0
4	CKD Associates with Cognitive Decline in Middle-Aged and Older Adults with Long-Standing Type 1 Diabetes. Kidney360, 2023, 4, 1058-1071.	1.4	6
5	MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 3214-3222.	3.1	21
6	Effects of metformin and intensive lifestyle interventions on the incidence of kidney disease in adults in the DPP/DPPOS. Journal of Diabetes and Its Complications, 2023, 37, 108556.	1.8	5
7	Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022. American Journal of Kidney Diseases, 2022, 79, 728-736.	1.0	68
8	Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. Diabetes Care, 2022, 45, 585-593.	5.6	7
9	Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 102-111.	12.4	50
10	Glucocorticoid receptor blockers. Pituitary, 2022, 25, 733-736.	2.0	27
11	Urinary Angiotensinogen in Patients With Type 1 Diabetes With Microalbuminuria: Gender Differences and Effect of Intensive Insulin Therapy. Kidney International Reports, 2022, 7, 2657-2667.	2.0	2
12	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, .	0.2	55
13	Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands. Frontiers in Endocrinology, 2021, 12, .	2.8	38
14	Prolactin and Other Pituitary Disorders in Kidney Disease. Seminars in Nephrology, 2021, 41, 156-167.	1.4	22
15	A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands. Journal of the Endocrine Society, 2021, 5, A517-A517.	0.2	5
16	Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly. Journal of the Endocrine Society, 2021, 5, A527-A528.	0.2	2
17	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	12.4	890
18	Growth hormone replacement in adults: Real-world data from two large studies in US and Europe. Growth Hormone and IGF Research, 2020, 50, 71-82.	1.0	13

#	Article	IF	Citations
19	An evaluation of recurrent hypoglycemia across Chicago, Illinois. Journal of Diabetes and Its Complications, 2020, 34, 107685.	1.8	1
20	Multidisciplinary management of acromegaly: A consensus. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 667-678.	5.1	331
21	Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3785-e3797.	3.1	90
22	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 2020, 382, 2493-2503.	26.4	361
23	A Pituitary Society update to acromegaly management guidelines. Pituitary, 2020, 24, 1-13.	2.0	301
24	Rebuttals to “The Debate on Insulin vs. Non-insulin Use in the Hospital Setting—Continued Use of Insulin or Time to Revise the Guidelines?”. Current Diabetes Reports, 2019, 19, .	4.1	0
25	Use of Insulin in the Inpatient Setting: Need for Continued Use. Current Diabetes Reports, 2019, 19, .	4.1	3
26	Pituitary Tumors in Pregnancy. Endocrinology and Metabolism Clinics of North America, 2019, 48, 569-581.	2.3	59
27	Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6238-6246.	3.1	29
28	Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus. Physiological Reports, 2019, 7, .	1.1	11
29	Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 854-861.	3.2	47
30	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol—Rationale, Design, and Baseline Data. Diabetes Care, 2019, 42, 1454-1463.	5.6	47
31	Risk Factors for Kidney Disease in Type 1 Diabetes. Diabetes Care, 2019, 42, 883-890.	5.6	124
32	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1520-1574.	3.1	498
33	OR22-4 Recurrent Hypoglycemia, Fragmentation of Care, and Mortality in Chicago. Journal of the Endocrine Society, 2019, 3, .	0.2	0
34	OR14-4 Early Glomerular Hyperfiltration and Long Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience. Journal of the Endocrine Society, 2019, 3, .	0.2	0
35	The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 681-688.	3.1	114
36	Development of a Predictive Model for Hyperglycemia in Nondiabetic Recipients After Liver Transplantation. Transplantation Direct, 2018, 4, e393.	1.3	1

#	Article	IF	Citations
37	Hyperglycemia in the Posttransplant Period: NODAT vs Posttransplant Diabetes Mellitus. Journal of the Endocrine Society, 2018, 2, 1314-1319.	0.2	21
38	Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. Lancet Diabetes and Endocrinology,the, 2018, 6, 879-890.	12.4	88
39	Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. Journal of Diabetes and Its Complications, 2018, 32, 1113-1117.	1.8	18
40	Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis. Endocrine, 2018, 61, 105-117.	1.8	5
41	Validation of data from electronic data warehouse in diabetic ketoacidosis: Caution is needed. Journal of Diabetes and Its Complications, 2018, 32, 650-654.	1.8	20
42	New Onset Diabetes After Transplant: Data from the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. American Journal of Medicine, 2018, 131, e347.	1.4	1
43	Lessons From the Testosterone Trials. Endocrine Reviews, 2018, 39, 369-386.	15.4	268
44	Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study. Journal of Clinical Endocrinology and Metabolism, 2017, , jc.2016-3279.	3.1	27
45	Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA - Journal of the American Medical Association, 2017, 317, 708.	14.4	360
46	Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. JAMA - Journal of the American Medical Association, 2017, 317, 717.	14.4	217
47	Association of Testosterone Levels With Anemia in Older Men. JAMA Internal Medicine, 2017, 177, 480.	7.7	232
48	Diagnosis and Treatment of Pituitary Adenomas. JAMA - Journal of the American Medical Association, 2017, 317, 516.	14.4	982
49	Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia, 2017, 60, 1601-1611.	4.9	175
50	Management of nonfunctioning pituitary adenomas (NFAs): observation. Pituitary, 2017, 21, 162-167.	2.0	51
51	Excellence in the treatment of patients with pituitary tumors. Pituitary, 2017, 21, 107-107.	2.0	5
52	A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry. Pituitary, 2017, 20, 605-618.	2.0	12
53	Evaluation of Outcomes and Complications in Patients Who Experience Hypoglycemia After Cardiac Surgery. Endocrine Practice, 2017, 23, 46-55.	2.0	12
54	Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels. Pituitary, 2016, 19, 601-604.	2.0	8

#	Article	IF	Citations
55	An Evaluation of Recurrent Diabetic Ketoacidosis, Fragmentation of Care, and Mortality Across Chicago, Illinois. Diabetes Care, 2016, 39, 1671-1676.	5.6	92
56	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1969-1977.	3.2	113
57	Inpatient Hypoglycemic Events in a Comparative Effectiveness Trial for Glycemic Control in a High-Risk Population. Endocrine Practice, 2016, 22, 1040-1047.	2.0	8
58	Diabetes Care After Transplant. Medical Clinics of North America, 2016, 100, 535-550.	2.2	49
59	Effects of Testosterone Treatment in Older Men. New England Journal of Medicine, 2016, 374, 611-624.	26.4	847
60	Recruitment and Screening for the Testosterone Trials. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 1105-1111.	2.4	29
61	Management of diabetes mellitus in patients with chronic kidney disease. Clinical Diabetes and Endocrinology, 2015, 1, .	1.5	118
62	Current approaches to the pharmacological management of Cushing's disease. Molecular and Cellular Endocrinology, 2015, 408, 185-189.	2.0	15
63	Cross-Disciplinary Biomarkers Research. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 894-902.	3.2	32
64	Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. Pituitary, 2015, 19, 138-148.	2.0	153
65	Letter to the Editor: Parathyroidectomy Halts the Deterioration of Renal Function in Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L98-L98.	3.1	2
66	Examination of Implementation of Intravenous and Subcutaneous Insulin Protocols and Glycemic Control in Heart Transplant Patients. Endocrine Practice, 2014, 20, 527-535.	2.0	14
67	The Authors Reply:. Kidney International, 2014, 86, 1270.	4.2	0
68	The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. Clinical Trials, 2014, 11, 362-375.	1.3	112
69	Insulin Therapy for Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2014, 311, 2315.	14.4	139
70	Longitudinal Changes in Estimated and Measured GFR in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2014, 25, 810-818.	0.2	45
71	Acromegaly: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3933-3951.	3.1	1,653
72	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. American Journal of Kidney Diseases, 2014, 64, 510-533.	1.0	524

#	Article	IF	Citations
73	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. Diabetes Care, 2014, 37, 2864-2883.	5.6	1,040
74	Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria. Journal of the American Society of Nephrology: JASN, 2014, 25, 2342-2350.	0.2	91
75	Surgical treatment of prolactinomas: cons. Endocrine, 2014, 47, 730-733.	1.8	27
76	Hyperglycemia and Insulin Resistance in Cardiac Arrest Patients Treated With Moderate Hypothermia. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2010-E2014.	3.1	16
77	Contextualized analysis of a needs assessment using the Theoretical Domains Framework: a case example in endocrinology. BMC Health Services Research, 2014, 14, .	1.6	2
78	Comparison of Glycemic and Surgical Outcomes After Change in Glycemic Targets in Cardiac Surgery Patients. Diabetes Care, 2014, 37, 2960-2965.	5.6	21
79	Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga. Diabetes Care, 2014, 37, 867-875.	5.6	173
80	We stand upon the shoulders of giants!. Pituitary, 2014, 18, 417-430.	2.0	0
81	Intensive glycemic control after heart transplantation is safe and effective for diabetic and non-diabetic patients. Clinical Transplantation, 2013, 27, 444-454.	1.0	21
82	A New Therapeutic Approach in the Medical Treatment of Cushing'S SYNDROME: GLUCOCORTICOID RECEPTOR BLOCKADE WITH MIFEPRISTONE. Endocrine Practice, 2013, 19, 313-326.	2.0	64
83	Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary, 2013, 17, 13-21.	2.0	48
84	Management of medically refractory prolactinoma. Journal of Neuro-Oncology, 2013, 117, 421-428.	1.9	150
85	A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency. Diabetes Care, 2012, 35, 1970-1974.	5.6	97
86	Transsphenoidal Surgery for Cushing Disease. Neurosurgery, 2012, 70, 70-81.	1.5	128
87	Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2039-2049.	3.1	474
88	Tumors invading the cavernous sinus that cause internal carotid artery compression are rarely pituitary adenomas. Pituitary, 2012, 15, 598-600.	2.0	22
89	Management of Incidentally Found Nonfunctional Pituitary Tumors. Neurosurgery Clinics of North America, 2012, 23, 543-553.	1.2	30
90	Circulating Vitamin D Metabolites and Kidney Disease in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4780-4788.	3.1	63

#	Article	IF	Citations
91	Management of Post-Transplant Diabetes. Current Diabetes Reports, 2012, 13, 121-129.	4.1	22
92	Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes. New England Journal of Medicine, 2011, 365, 2366-2376.	26.4	553
93	Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 894-904.	3.1	565
94	Prolactinoma in pregnancy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 885-896.	3.4	106
95	Glycemic Control by A Glucose Management Service and Infection Rates After Liver Transplantation. Endocrine Practice, 2011, 17, 546-551.	2.0	40
96	Positive Prolactin Response to Bromocriptine in 2 Patients with Cabergoline-Resistant Prolactinomas. Endocrine Practice, 2011, 17, e55-e58.	2.0	26
97	Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1587-1609.	3.1	804
98	Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria<subtitle>An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort</subtitle><alt-title>Microalbuminuria Outcomes in Type 1 Diabetes</alt-title>. Archives of Internal Medicine, 2011, 171, 412.	8.1	332
99	Patient Guide to Growth Hormone Deficiency in Adults. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 33A-34A.	3.1	1
100	Posttransplant Hyperglycemia is Associated With Increased Risk of Liver Allograft Rejection. Transplantation, 2010, 89, 222-226.	1.4	91
101	High Prevalence and Diversity of Kidney Dysfunction in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The BARI 2D Baseline Data. American Journal of the Medical Sciences, 2010, 339, 401-410.	0.3	18
102	Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2010, 33, 1536-1543.	5.6	281
103	Comparison of Urinary Albumin-Creatinine Ratio and Albumin Excretion Rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1235-1242.	3.2	55
104	National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney International, 2010, 78, 726-736.	4.2	52
105	Diabetes, Cardiovascular Risk and Nephropathy. Cardiology Clinics, 2010, 28, 467-475.	0.7	28
106	A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. New England Journal of Medicine, 2009, 360, 2503-2515.	26.4	1,833
107	Is Lack of Recombinant Growth Hormone (GH)-Releasing Hormone in the United States a Setback or Time to Consider Glucagon Testing for Adult GH Deficiency?. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2702-2707.	3.1	80
108	Pituitary incidentalomas. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 667-675.	3.4	154

#	Article	IF	Citations
109	Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly. Pituitary, 2009, 13, 115-122.	2.0	62
110	The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. Pituitary, 2009, 13, 266-286.	2.0	9
111	Primary CNS lymphoma with bilateral symmetric hypothalamic lesions presenting with panhypopituitarism and diabetes insipidus. Pituitary, 2009, 14, 194-197.	2.0	24
112	Drugs and prolactin. Pituitary, 2008, 11, 209-218.	2.0	159
113	Insulin resistance following cardiothoracic surgery in patients with and without a preoperative diagnosis of type 2 diabetes during treatment with intravenous insulin therapy for postoperative hyperglycemia. Journal of Diabetes and Its Complications, 2008, 22, 229-234.	1.8	13
114	Nonfunctioning Pituitary Tumors and Pituitary Incidentalomas. Endocrinology and Metabolism Clinics of North America, 2008, 37, 151-171.	2.3	175
115	The Cabergoline-Resistant Prolactinoma Patient: New Challenges. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4643-4645.	3.1	43
116	Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus. Archives of Internal Medicine, 2008, 168, 1867.	8.1	114
117	Management of Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Endocrine Practice, 2008, 14, 18-27.	2.0	52
118	La diabetes y la terapia basada en la incretina. Journal of Clinical Endocrinology and Metabolism, 2007, 92, E2-E2.	3.1	0
119	Guías de la Pituitary Society para el diagnóstico y tratamiento de los prolactinomas. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2007, 54, 438.e1-438.e10.	1.0	2
120	One View of Hospitalization. Endocrine Practice, 2007, 13, 202-203.	2.0	0
121	Diabetes and Incretin-based Therapy. Journal of Clinical Endocrinology and Metabolism, 2007, 92, E1-E1.	3.1	0
122	Pituitary Disorders During Pregnancy. Endocrinology and Metabolism Clinics of North America, 2006, 35, 99-116.	2.3	64
123	Conversion of Intravenous Insulin Infusions to Subcutaneously Administered Insulin Glargine in Patients With Hyperglycemia. Endocrine Practice, 2006, 12, 641-650.	2.0	100
124	Inpatient Management of Hyperglycemia: The Northwestern Experience. Endocrine Practice, 2006, 12, 491-505.	2.0	98
125	Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology, 2006, 65, 265-273.	1.5	794
126	Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1621-1634.	3.1	417

#	Article	IF	Citations
127	Advances in the Treatment of Prolactinomas. Endocrine Reviews, 2006, 27, 485-534.	15.4	770
128	Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1090-1099.	3.2	56
129	Prolactin-secreting tumors: what's new?. Expert Review of Anticancer Therapy, 2006, 6, S29-S35.	1.5	17
130	Diabetes Tipo 1. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 0-0.	3.1	1
131	Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2005, 90, E2-E2.	3.1	5
132	Pharmacologic Resistance in Prolactinoma Patients. Pituitary, 2005, 8, 43-52.	2.0	187
133	The Pituitary Mass: Diagnosis and Management. Reviews in Endocrine and Metabolic Disorders, 2005, 6, 55-62.	5.1	24
134	The incidence of Sheehan's syndrome after obstetric hemorrhage. Fertility and Sterility, 2005, 84, 975-979.	2.2	64
135	Medication-Induced Hyperprolactinemia. Mayo Clinic Proceedings, 2005, 80, 1050-1057.	1.9	246
136	Diabetes and Hypertension: Pathogenesis, Prevention and Treatment. Clinical and Experimental Hypertension, 2004, 26, 621-628.	3.7	93
137	Cortisol levels and mortality in severe sepsis. Clinical Endocrinology, 2004, 60, 29-35.	1.5	143
138	La diabetes tipo 2 y la prueba A1c. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 0-0.	3.1	0
139	Type 2 Diabetes and A1c. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 0-0.	3.1	0
140	Title is missing!. Pituitary, 2003, 6, 19-27.	2.0	93
141	Title is missing!. Pituitary, 2003, 6, 5-10.	2.0	11
142	Epigenetic and genetic analysis of p16 in dermal fibroblasts from type 1 diabetic patients with nephropathy. Kidney International, 2003, 63, 2094-2102.	4.2	5
143	Timing and special concerns regarding endocrine surgery during pregnancy. Endocrinology and Metabolism Clinics of North America, 2003, 32, 337-354.	2.3	61
144	Pituitary tumors and pregnancy. Growth Hormone and IGF Research, 2003, 13, S38-S44.	1.0	89

#	Article	IF	Citations
145	The Novel Use of Very High Doses of Cabergoline and a Combination of Testosterone and an Aromatase Inhibitor in the Treatment of a Giant Prolactinoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4447-4451.	3.1	96
146	Diagnosis of GH Deficiency in Adults—How Good Do the Criteria Need to Be?. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 473-476.	3.1	24
147	The relationship between glucose control and the development and progression of diabetic nephropathy. Current Diabetes Reports, 2002, 2, 523-529.	4.1	27
148	Title is missing!. Pituitary, 2002, 5, 55-65.	2.0	98
149	Diagnosis of GH Deficiency in Adults--How Good Do the Criteria Need to Be?. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 473-476.	3.1	13
150	Endocrine Problems in the Chronically Critically Ill Patient. Clinics in Chest Medicine, 2001, 22, 193-208.	1.6	22
151	DISORDERS OF PROLACTIN SECRETION. Endocrinology and Metabolism Clinics of North America, 2001, 30, 585-610.	2.3	158
152	Rise in Albuminuria and Blood Pressure in Patients Who Progressed to Diabetic Nephropathy in the Diabetes Control and Complications Trial. Journal of the American Society of Nephrology: JASN, 2001, 12, 333-340.	0.2	24
153	Corticotropin-Releasing Hormone-Producing Medullary Thyroid Carcinoma Causing Cushing's Syndrome: Clinical and Pathological Findings. Endocrine Pathology, 2000, 11, 277-286.	2.2	7
154	Growth Hormone Therapy for Hypopituitary Adults: Time for Re-appraisal. Trends in Endocrinology and Metabolism, 2000, 11, 238-245.	8.0	21
155	10.1016/b978-0-323-60974-6.00043-8. Time To Knit, 2000, , .	0.0	0
156	MEDICAL TREATMENT OF PROLACTINOMAS. Endocrinology and Metabolism Clinics of North America, 1999, 28, 143-169.	2.3	146
157	Pituitary diseases in pregnancy. Seminars in Perinatology, 1998, 22, 457-470.	1.7	77
158	Postoperative Radiotherapy for Clinically Nonfunctioning Pituitary Adenomas. , 1998, 8, 71-78.		9
159	The Case for Initial Surgical Removal of Certain Prolactinomas. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 996-1000.	3.1	134
160	PITUITARY INCIDENTALOMAS. Endocrinology and Metabolism Clinics of North America, 1997, 26, 725-740.	2.3	79
161	Management of Early Diabetic Nephropathy. American Journal of Medicine, 1997, 102, 392-398.	1.4	32
162	The Case for Initial Surgical Removal of Certain Prolactinomas. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 996-1000.	3.1	57

#	Article	IF	Citations
163	Evaluation and Management of Pituitary Tumors During Pregnancy. Endocrine Practice, 1996, 2, 287-295.	2.0	10
164	Cerebrovascular disorders in patients with diabetes mellitus. Journal of Diabetes and Its Complications, 1996, 10, 228-242.	1.8	118
165	Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2338-2343.	3.1	175
166	Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 2768-2775.	3.1	219
167	Clinical review 65. Evaluation and treatment of the patient with a pituitary incidentaloma. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 3-6.	3.1	116
168	Pituitary Adenomas. Annals of Internal Medicine, 1995, 122, 476.	7.3	3
169	Baseline analysis of renal function in the Diabetes Control and Complications Trial. Kidney International, 1993, 43, 668-674.	4.2	65
170	New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist.. Journal of Clinical Endocrinology and Metabolism, 1993, 76, 1363-1368.	3.1	34
171	Incidental Pituitary Adenomas. American Journal of the Medical Sciences, 1993, 306, 262-264.	0.3	33
172	Endocrine Problems of Adolescent Pregnancy. Endocrinology and Metabolism Clinics of North America, 1993, 22, 649-672.	2.3	1
173	Effects of Calcium Channel Blockade withVerapamil on the Prolactin Responsesto TRH, L-Dopa, and Bromocriptine. American Journal of the Medical Sciences, 1992, 304, 289-293.	0.3	12
174	Octreotide Treatment of Acromegaly. Annals of Internal Medicine, 1992, 117, 711-718.	7.3	261
175	10 Endocrine emergencies in pregnancy. Bailliere's Clinical Endocrinology and Metabolism, 1992, 6, 167-191.	1.9	36
176	Pathologic Hyperprolactinemia. Endocrinology and Metabolism Clinics of North America, 1992, 21, 877-901.	2.3	120
177	Clinical Manifestations of Acromegaly. Endocrinology and Metabolism Clinics of North America, 1992, 21, 597-614.	2.3	197
178	Unaltered Drug Metabolizing Enzyme Systems in Type II Diabetes Mellitus Before and During Glyburide Therapy. Journal of Clinical Pharmacology, 1990, 30, 943-947.	1.3	9
179	Treatment of Prolactin-Secreting Pituitary Macroadenomas with the Long-acting Non-Ergot Dopamine Agonist CV 205-502. Annals of Internal Medicine, 1990, 112, 668-673.	7.3	72
180	Inhibition of Follicle-Stimulating Hormone Secretion from Gonadotroph Adenomas by Repetitive Administration of a Gonadotropin-Releasing Hormone Antagonist*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 92-97.	3.1	35

#	Article	IF	Citations
181	Endocrinology. JAMA - Journal of the American Medical Association, 1990, 263, 2639.	14.4	0
182	Effect of Angiotensin-Converting Enzyme Inhibition on Pituitary Hormone Responses to Insulin-Induced Hypoglycemia in Humans*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 256-259.	3.1	13
183	Occurrence of Intercapillary Nodular Glomerulosclerosis in the Absence of Glucose Intolerance. American Journal of Kidney Diseases, 1990, 15, 281-283.	1.0	13
184	Management of Prolactinomas. Annual Review of Medicine, 1989, 40, 225-232.	10.5	34
185	CV 205–502 Treatment of Hyperprolactinemia*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 336-339.	3.1	65
186	Diabetes mellitus. Postgraduate Medicine, 1989, 85, 182-194.	1.5	8
187	Comparison of Ease of Learning of Four Glucose Meters. The Diabetes Educator, 1988, 14, 313-315.	2.9	1
188	The effect of the ergoline derivative, CU 32-085, on prolactin secretion in hyperprolactinemic women. Fertility and Sterility, 1987, 48, 555-559.	2.2	2
189	Pharmacokinetic Studies of Highly Purified Human Prolactin in Normal Human Subjects*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 299-304.	3.1	14
190	A new strategy for clinical decision making: Censors and neuroendocrinological diseases. Computers in Biology and Medicine, 1986, 16, 215-221.	4.5	1
191	Delayed chiasmal decompression after transsphenoidal operation for a pituitary adenoma. Neurosurgery, 1985, 17, 962???4.	1.5	0
192	Delayed Chiasmal Decompression after Transsphenoidal Operation for a Pituitary Adenoma. Neurosurgery, 1985, 17, 962-964.	1.5	10
193	Effects of Growth Hormone-Releasing Factor on Growth Hormone Secretion in Acromegaly∗. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 251-257.	3.1	63
194	Bromocriptine as Primary Therapy for Prolactin-Secreting Macroadenomas: Results of a Prospective Multicenter Study*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 698-705.	3.1	441
195	Pregnancy and the Hyperprolactinemic Woman. New England Journal of Medicine, 1985, 312, 1364-1370.	26.4	262
196	Case 5-1985. New England Journal of Medicine, 1985, 312, 297-305.	26.4	30
197	Vasoactive Intestinal Peptide Is a Physiological Mediator of Prolactin Release in the Rat*. Endocrinology, 1985, 116, 1383-1390.	1.8	267
198	Hyperprolactinemia in Patients With Renal Insufficiency and Chronic Renal Failure Requiring Hemodialysis or Chronic Ambulatory Peritoneal Dialysis. American Journal of Kidney Diseases, 1985, 6, 245-249.	1.0	122

#	Article	IF	Citations
199	Reversible hyperthyrotropinemia, hyperthyroxinemia, and hyperprolactinemia due to adrenal insufficiency. American Journal of Medicine, 1985, 79, 271-276.	1.4	52
200	The Cold Thyroid Nodule: An Analysis of Diagnostic and Therapeutic Options*. Endocrine Reviews, 1984, 5, 185-199.	15.4	92
201	Long-term Follow-up of Transsphenoidal Selective Adenomectomy for Prolactinoma. JAMA - Journal of the American Medical Association, 1984, 252, 921.	14.4	68
202	Cavernous sinus syndrome due to prolactinoma: Resolution with bromocriptine. World Neurosurgery, 1983, 19, 280-284.	1.3	21
203	Neuroendocrine alterations in systemic disease. Clinics in Endocrinology and Metabolism, 1983, 12, 825-851.	2.6	23
204	Aging and the thyroid. American Journal of Medicine, 1983, 75, 206-209.	1.4	136
205	Case 25-1983. New England Journal of Medicine, 1983, 308, 1521-1529.	26.4	6
206	Agranulocytosis Associated with Antithyroid Drugs. Annals of Internal Medicine, 1983, 98, 26-29.	7.3	223
207	Endocrinology and Metabolism. JAMA - Journal of the American Medical Association, 1982, 247, 1051.	14.4	0
208	Surgical Cure of Prolactinoma Reverses Abnormal Prolactin Response to Carbidopa/L-Dopa*. Journal of Clinical Endocrinology and Metabolism, 1982, 55, 1118-1123.	3.1	17
209	Hyperprolactinemic disorders. Disease-a-Month, 1982, 28, 6-58.	2.3	22
210	Is prolactin secreted ectopically?. American Journal of Medicine, 1981, 70, 803-807.	1.4	35
211	Bromocriptine Therapy in Acromegaly: Use in Patients Resistant to Conventional Therapy and Effect on Serum Levels of Somatomedin C*. Journal of Clinical Endocrinology and Metabolism, 1981, 53, 752-758.	3.1	53
212	Clinical Cardiology and Diabetes, vol 3, part 1: Clinical Manifestations, Medical Management; part 2: Surgical Management, Renal Disease, Special Problems. JAMA - Journal of the American Medical Association, 1981, 246, 1256.	14.4	0
213	Lack of Modulation of Pituitary Hormone Stress Response by Neural Pathways Involving Opiate Receptors*. Journal of Clinical Endocrinology and Metabolism, 1980, 50, 516-520.	3.1	80
214	Galactorrhea, Oligo/Amenorrhea, and Hyperprolactinemia in Patients with Craniopharyngiomas*. Journal of Clinical Endocrinology and Metabolism, 1980, 51, 798-800.	3.1	53
215	Altered thyroid hormone levels in bacterial sepsis: The role of nutritional adequacy. Metabolism: Clinical and Experimental, 1980, 29, 936-942.	8.9	47
216	The Value of Computed Tomography in Evaluating Patients with Prolactinomas. Radiology, 1979, 131, 117-119.	6.7	33

#	Article	IF	Citations
217	Selective Transsphenoidal Adenomectomy in Women With Galactorrhea-Amenorrhea. JAMA - Journal of the American Medical Association, 1979, 242, 158.	14.4	88
218	Eosinophilic granuloma mimicking a pituitary tumor. Neurosurgery, 1979, 5, 723???5.	1.5	2
219	Eosinophilic Granuloma Mimicking a Pituitary Tumor. Neurosurgery, 1979, 5, 723-725.	1.5	23
220	Pseudonursing: a case of galactorrhea. American Journal of Psychiatry, 1979, 136, 223-224.	5.1	10
221	Thyroid Supplements and Breast Cancer. JAMA - Journal of the American Medical Association, 1976, 236, 2746.	14.4	1
222	Hyperlipemia During Estrogen Therapy. JAMA - Journal of the American Medical Association, 1974, 230, 373.	14.4	0
223	Massive Hyperlipemia During Estrogen Therapy. JAMA - Journal of the American Medical Association, 1974, 227, 522.	14.4	66
224	Title is missing!. , 0, .		1
225	Title is missing!. , 0, .		1
226	Title is missing!. , 0, .		1
227	Title is missing!. , 0, .		1
228	Debate: Surgery as Initial Therapy for Microprolactinoma. Journal of Clinical Endocrinology and Metabolism, 0, 110, e4242-e4247.	3.1	3